Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

IPIX email: This morning the Company reported the following information to the UNITED STATES SECURITIES AND EXCHANGE COMMISSION on a Form 8-K.


Item 7.01 Regulation FD Disclosure.

On October 23, 2018, Innovation Pharmaceuticals Inc. (the “Company”) was informed by the U.S. Food and Drug Administration (“FDA”) that the Company’s request for an End of Phase 2 meeting regarding the Company’s oral mucositis program was granted. The meeting is scheduled for later this quarter and is focused on obtaining FDA’s guidance about the Company’s proposed development plan and review of the Company’s clinical trial of Brilacidin for the indication of decreasing the incidence of severe oral mucositis in head and neck cancer patients receiving chemoradiation.